This listing is the Japan-manufactured edition of Melsmon. It is an injectable human placenta extract given by subcutaneous injection – it is not an oral supplement. Melsmon has been in clinical use in Japan since its approval in 1956 and is recognized for the relief of menopausal symptoms and support for poor lactation after childbirth. It is a prescription product for professional use.

It indicates this is the edition manufactured in Japan. The composition is the same as standard Melsmon – each 2ml ampoule contains 100mg of human placenta extract, prepared from frozen fresh placenta by a dedicated method. It is supplied as an injectable, the same as the regular Melsmon listing.

It contains a range of amino acids and nucleic acid substances, minerals and growth factors among its recognized components – the substances naturally present in placenta. The activity is associated with the whole extract rather than any single isolated compound.

Its recognized indications are the relief of various menopausal disorder symptoms and support for poor lactation after childbirth. The decision to use it, and patient suitability, are determined by the treating professional.

As a human-derived prescription product, Melsmon must be administered only by licensed medical professionals, not self-administered. It should be avoided in pregnancy, breastfeeding and in anyone with known hypersensitivity to its components. Patient suitability is assessed by the treating professional.